Tryngolza charts blockbuster course after FDA’s hypertriglyceridemia approval

▤ Summary

Ionis received FDA approval to expand Tryngolza into severe hypertriglyceridemia, making it the only approved targeted therapy shown to reduce pancreatitis risk in this patient group. The approval was based on Phase III CORE and CORE2 results that showed major triglyceride reductions and fewer acute pancreatitis events. Ionis says the label expansion strengthens its path toward a first wholly owned blockbuster and supports a peak sales target of $2 billion. Investors will also watch competing late-stage data from Arrowhead as the market for sHTG treatments develops.

▦ Linked Companies